Non-Small Cell Lung Cancer Clinical Trials

A listing of 133 Non-Small Cell Lung Cancer clinical trials actively recruiting volunteers for paid trials and research studies in various therapeutic areas.

Home

All Conditions

Non-Small Cell Lung Cancer

Show Filters

Match to Clinical Trials

Access to cutting-edge treatments

Latest clinical trials

Find trials in your area

Start Matching

Filter by Age

There are currently 133 active clinical trials seeking participants for Non-Small Cell Lung Cancer research studies. The states with the highest number of trials for Non-Small Cell Lung Cancer participants are California, Texas, Florida and New York.

Featured Trial

Paid Clinical Studies Nationwide

Recruiting

Nationwide clinical trials offered in your area. Some trials offering up to several thousand dollars in compensation for participation.

Conditions:

Healthy

Healthy Volunteer Study

Learn More

* Compensation for time may be available

Featured Trial

Chronic Cough Research Study

Recruiting

Are you tired of living with chronic cough? Our research study is now looking to enroll people from all backgrounds to help research potential new treatment options for chronic cough.
You are under no obligation to take part and health insurance is not required. Find out more today! We’d love to hear from you!

Conditions:

Chronic Cough

Refractory or Unexplained Chronic Cough

Cough

Asthma

Sinusitis

Learn More

Featured Offer

Lose Weight with GLP-1 Medications

Recruiting

Policy Lab has partnered with OnlineSemaglutide.org to offer trusted access to semaglutide and other GLP-1 medications, including generic alternatives to Ozempic® and Wegovy®.

GLP-1 medications are scientifically backed to help individuals achieve significant weight loss—on average, 15-20% of body weight within a year.

As a valued user, you’re eligible for $100 off your first program with code policy-lab-100.

Conditions:

Overweight

Overweight and Obesity

Obesity

Weight Loss

Morbid Obesity

Learn More

Featured Trial

Stroke Clinical Study

Recruiting

A clinical study for people that suffer with Stroke

Conditions:

Stroke

Learn More

Safety, Effectiveness, and Pharmacokinetics of BNT327 in Combination With Chemotherapy and Other Investigational Agents for Lung Cancer

NCT06712316

Recruiting

This is a Phase 2/3, multisite, randomized, open-label study in participants with first-line non-small cell lung cancer (NSCLC). This study includes two substudies (substudy A and substudy B) that will recruit participants according to histological subtypes due to differences in chemotherapy choice for standard-of-care and type of NSCLC.

Gender:

ALL

Ages:

18 years and above

Trial Updated:

08/13/2025

Locations: Alaska Oncology and Hematology, LLC, Anchorage, Alaska +98 locations

Alaska Oncology and Hematology, LLC, Anchorage, Alaska

Clermont Oncology Center, Clermont, Florida

Physicians Clinic of Iowa, Cedar Rapids, Iowa

Holden Comprehensive Cancer Center, University of Iowa Hospitals and Clinics, Iowa City, Iowa

Baptist Health, Lexington, Kentucky

SSM Health Cancer Care - St. Clare, Fenton, Missouri

Mary Lanning Healthcare (MLH) - Morrison Cancer Center (MCC), Hastings, Nebraska

Astera Cancer Care, East Brunswick, New Jersey

The Valley Hospital - Valley Health System - The Robert and Audrey Luckow Pavilion, Paramus, New Jersey

White Plains Hospital, White Plains, New York

Fletcher Hospital, Inc. dba AdventHealth Hendersonville, Hendersonville, North Carolina

University of Cincinnati Medical Center, Cincinnati, Ohio

University of Tennessee Medical Center, Knoxville, Tennessee

Baptist Cancer Center, Memphis, Tennessee

Millennium Research and Clinical Development, LLC, Houston, Texas

Royal Adelaide Hospital, Adelaide, Not set

Cairns Hospital, Cairns, Not set

Dubbo Hospital, Dubbo, Not set

Peninsula & South Eastern Haematology and Oncology Group, Frankston, Not set

Icon Cancer Centre Kurralta Park, Kurralta Park, Not set

Western Health Sunshine Hospital, St Albans, Not set

ICON Cancer Care - Townsville, Townsville, Not set

Cancer Care Wollongong Pty Limited, Wollongong, Not set

Universitair Ziekenhuis Leuven, Leuven, Not set

CHU HELORA, Hopital de Mons - Site Kennedy, Mons, Not set

Shandong University - Jinan Central Hospital, Jinan, Not set

Shanghai Chest Hospital, Shanghai, Not set

Cancer Hospital of Shantou University Medical College, Shantou, Not set

Centre Hospitalier Universitaire d'Angers (CHU Angers), Angers, Not set

Institut Bergonie - Centre Regional de Lutte Contre Le Cancer de Bordeaux et Sud Ouest, Bordeaux, Not set

CHU Caen Normandie, Caen, Not set

Centre Francois Baclesse, Caen, Not set

Centre Hospitalier Intercommunal de Creteil (CHIC) - Centre de ressources et de competences pour la mucoviscidose (C.R.C.M.), Créteil, Not set

Institut de Cancerologie de l'Ouest (ICO)- CRLCC Rene Gauducheau, Saint-Herblain, Not set

Centre Hospitalier Intercommunal Toulon La Seyne Sur Mer (C.H.I.T.S) - Hospital Font-Pre, Toulon, Not set

Klinikum Esslingen GmbH, Esslingen, Not set

Asklepios Fachkliniken Muenchen Gauting, Gauting, Not set

Lungenfachklinik Immenhausen - Pneumologische Lehrklinik der Universitaet Goettingen, Immenhausen, Not set

MVZ for oncology and hematology Rhein-Kreis Neuss GmbH, Neuss, Not set

Praxiskooperation Bonn-Euskirchen-Rheinbach-Wesseling, Wesseling, Not set

Azienda Ospedaliera San Giuseppe Moscati, Avellino, Not set

Centro di Riferimento Oncologico, Aviano, Not set

IRCCS Istituto Romagnolo per lo studio dei Tumori Dino Amadori (IRST), Meldola, Not set

Casa Di Cura Polispecialistica Dott Pederzoli, Peschiera del Garda, Not set

Fondazione Policlinico Universitario Campus Bio-Medico, Roma, Not set

Fondazione Ospedale Isola Tiberina - Gemelli Isola, Rome, Not set

Chungbuk National University Hospital, Cheongju-si, Not set

Chungnam National University Hospital (CNUH), Daejeon, Not set

National Cancer Center, Goyang-si, Not set

Gachon University Gil Medical Center, Incheon, Not set

Gyeongsang National University Hospital (GNUH), Jinju-si, Not set

Severance Hospital, Yonsei University Health System, Seoul, Not set

Asan Medical Center (AMC), Seoul, Not set

Samsung Medical Center, Seoul, Not set

Korea University Guro Hospital, Seoul, Not set

The Catholic University Of Korea, St. Vincent's Hospital, Suwon-si, Not set

Ajou University Hospital, Suwon-si, Not set

NZOZ Medpolonia Sp. Z o.o., Poznan, Not set

Wojewodzki Szpital im. Sw. Ojca Pio w Przemyslu, Przemyśl, Not set

Instytut MSF Sp. z o.o., Łódź, Not set

Cardiomed, Cluj-Napoca, Not set

S.C. Medisprof S.R.L, Oncologie medicala, Cluj-Napoca, Not set

Radiotherapy Center Cluj, Cluj, Not set

Onco Clinic Consult SA, Craiova, Not set

Centrul de Oncologie Sf. Nectarie S.R.L (Sf Nectarie Oncology Center), Craiova, Not set

Ovidius Clinical Hospital, Ovidiu, Not set

Oncomed, Timisoara, Not set

Hospital Universitario Nuestra Senora De Valme, Sevilla, Not set

Hospital Universitario Virgen del Rocio, Seville, Not set

Adana City Training and Research Hospital, Adana, Not set

Gulhane Training and Research Hospital, Ankara, Not set

Dr. Abdurrahman Yurtaslan Ankara Oncology Training and Research Hospital, Ankara, Not set

Hacettepe University Medicine Faculty, Ankara, Not set

Memorial Ankara Hospital, Ankara, Not set

Liv Hospital Ankara, Ankara, Not set

Ankara Bilkent City Hospital, Ankara, Not set

Akdeniz University Hospital, Antalya, Not set

Gaziantep Sanko University Medical Faculty, Gaziantep, Not set

Bezmialem Foundation University Medical Faculty, Istanbul, Not set

Yeditepe University Kosuyolu Hospital, Istanbul, Not set

Medical Point Izmir Hospital, İzmir, Not set

Goztepe Prof. Dr. Suleyman Yalcin City Hospital, Kadıköy, Not set

Kocaeli Universitesi Tip Fakultesi, Kocaeli, Not set

Medical Park Florya Hospital, Kucukcekmece, Not set

Sakarya University - Faculty of Medicine, Sakarya, Not set

Ondokuz Mayis University Health Practice and Research Hospital, Samsun, Not set

Acibadem Adana Hospital, Seyhan, Not set

Medical Park Seyhan Hospital, Seyhan, Not set

Gazi University Faculty of Medicine, Yenimahalle, Not set

Koc Universitesi Hastanesi (Koc University Hospital), Zeytinburnu, Not set

Royal Sussex County Hospital - University Hospitals Sussex NHS Foundation Trust, Brighton, Not set

Velindre NHS Trust, Velindre Cancer Centre, Cardiff, Not set

Hull University Teaching Hospitals NHS Trust, Cottingham, Not set

University College Hospital, London, Not set

The Christie NHS Foundation Trust, Manchester, Not set

Cancer And Haematology Centre-The Churchill Hospital-Oxford University Hospitals, Oxford, Not set

Royal Preston Hospital - Lancashire Teaching Hospitals NHS Foundation Trust, Preston, Not set

Southampton General Hospital, Southampton, Not set

New Cross Hospital, Wolverhampton, Not set

Conditions: Non-small Cell Lung Cancer

Learn More ›

A Study of Intismeran Autogene (V940) Plus Pembrolizumab (MK-3475) Versus Placebo Plus Pembrolizumab in Participants With Non-small Cell Lung Cancer (V940-002)

NCT06077760

Recruiting

The goal of this study is to evaluate intismeran autogene plus pembrolizumab versus placebo plus pembrolizumab for the adjuvant treatment of margin negative, completely resected Stage II, IIIA, IIIB (with nodal involvement \[N2\]) non-small cell lung cancer (NSCLC). The primary hypothesis is that intismeran autogene plus pembrolizumab is superior to placebo plus pembrolizumab with respect to disease-free survival (DFS) as assessed by the investigator.

Gender:

ALL

Ages:

18 years and above

Trial Updated:

08/13/2025

Locations: Alaska Oncology and Hematology ( Site 0039), Anchorage, Alaska +198 locations

Alaska Oncology and Hematology ( Site 0039), Anchorage, Alaska

The University of Arizona Cancer Center - North Campus ( Site 0071), Tucson, Arizona

YUMA REGIONAL MEDICAL CENTER CANCER CENTER ( Site 0020), Yuma, Arizona

UCLA Clinical & Translational Research Center (CTRC) ( Site 0059), Los Angeles, California

St. Joseph Hospital-The Center for Cancer Prevention and Treatment ( Site 0074), Orange, California

University of California, Irvine (UCI) Health - UC Irvine Medical Center ( Site 0030), Orange, California

UCHealth Memorial Hospital-Heme Onc ( Site 0052), Colorado Springs, Colorado

Mayo Clinic Florida ( Site 4043), Jacksonville, Florida

Mid Florida Hematology and Oncology Center ( Site 0014), Orange City, Florida

AdventHealth Orlando-AdventHealth Medical Group Hematology & Oncology at Orlandoc ( Site 0013), Orlando, Florida

Moffitt Cancer Center ( Site 0078), Tampa, Florida

Northwest Georgia Oncology Centers, a Service of Wellstar Cobb Hospital ( Site 0012), Marietta, Georgia

Southeastern Regional Medical Center ( Site 0098), Newnan, Georgia

Beacon Cancer Care ( Site 0044), Post Falls, Idaho

University of Iowa-Holden Comprehensive Cancer Center ( Site 0062), Iowa City, Iowa

Saint Elizabeth Healthcare ( Site 0092), Edgewood, Kentucky

The University of Louisville, James Graham Brown Cancer Center ( Site 0037), Louisville, Kentucky

University of Michigan Clinical Trials Office ( Site 0058), Ann Arbor, Michigan

Cancer and Hematology Centers of Western Michigan ( Site 4003), Grand Rapids, Michigan

St. Vincent Frontier Cancer Center ( Site 0043), Billings, Montana

NHO Revive Research Institute, LLC ( Site 4009), Lincoln, Nebraska

John Theurer Cancer Center at Hackensack University Medical Center ( Site 0036), Hackensack, New Jersey

Atlantic Health Morristown Medical Center ( Site 4018), Morristown, New Jersey

New York Oncology Hematology, P.C. ( Site 4012), Albany, New York

Montefiore Medical Center- Montefiore Medical Park-Oncology ( Site 0080), Bronx, New York

Perlmutter Cancer Center at NYU Langone Hospital - Long Island-Clinical Research Department ( Site 0095), Mineola, New York

Laura and Isaac Perlmutter Cancer Center ( Site 0010), New York, New York

Icahn School of Medicine at Mount Sinai ( Site 0034), New York, New York

Columbia University Irving Medical Center-CUIMC Herbert Irving Comprehensive Cancer Center Clinical ( Site 0054), New York, New York

Memorial Sloan Kettering Cancer Center ( Site 0029), New York, New York

Stony Brook University-Cancer Center ( Site 0072), Stony Brook, New York

Sanford Fargo Medical Center-Roger Maris Cancer Center ( Site 0063), Fargo, North Dakota

Altru Health System ( Site 0040), Grand Forks, North Dakota

Summa Health ( Site 4011), Akron, Ohio

University of Cincinnati Medical Center-University of Cincinnati Cancer Center ( Site 0028), Cincinnati, Ohio

University Hospitals Cleveland Medical Center ( Site 0023), Cleveland, Ohio

OSU Brain and Spine Hospital ( Site 0016), Columbus, Ohio

Good Samaritan Regional Medical Center-Samaritan Pastega Regional Cancer Center ( Site 0082), Corvallis, Oregon

Thomas Jefferson University - Clinical Research Institute ( Site 0006), Philadelphia, Pennsylvania

Medical University of South Carolina-Hollings Cancer Center ( Site 0050), Charleston, South Carolina

Sanford Cancer Center ( Site 0075), Sioux Falls, South Dakota

Thompson Cancer Survival Center ( Site 0097), Knoxville, Tennessee

One Oncology - Tennessee Oncology ( Site 4019), Nashville, Tennessee

SCRI Oncology Partners ( Site 7001), Nashville, Tennessee

UT Southwestern Medical Center ( Site 0061), Dallas, Texas

Inova Schar Cancer Institute ( Site 0003), Fairfax, Virginia

Swedish Medical Center-Swedish Cancer Institute ( Site 0088), Seattle, Washington

Fred Hutchinson Cancer Center ( Site 0002), Seattle, Washington

Edwards Comprehensive Cancer Center ( Site 4015), Huntington, West Virginia

Clinica Adventista Belgrano-Oncology ( Site 2901), Caba., Buenos Aires

Hospital Italiano de Buenos Aires-Clinical Oncology ( Site 2912), Ciudad Autonoma de Buenos Aires, Buenos Aires

Instituto Alexander Fleming ( Site 2911), Ciudad Autónoma de Buenos Aires, Buenos Aires

Instituto de Investigaciones Clínicas Mar del Plata ( Site 2908), Mar del Plata, Buenos Aires

Fundacion Estudios Clinicos-Oncology ( Site 2907), Rosario, Santa Fe

Sanatorio Parque ( Site 2904), Rosario, Santa Fe

Peter MacCallum Cancer Centre-Parkville Cancer Clinical Trials Unit (PCCTU) ( Site 0203), Melbourne, Victoria

St Vincent's Hospital-Oncology Clinical Trials ( Site 0202), Melbourne, Victoria

One Clinical Research ( Site 0200), Nedlands, Western Australia

Antwerp University Hospital-Thoracic Oncology ( Site 0603), Edegem, Antwerpen

Université Catholique de Louvain-Namur - Centre Hospitalier Universitaire Dinant-Godinne - Site Godi ( Site 0602), Yvoir, Namur

AZORG Campus Aalst-Moorselbaan ( Site 0604), Aalst, Oost-Vlaanderen

VITAZ ( Site 0600), Sint-Niklaas, Oost-Vlaanderen

CRIO - CENTRO REGIONAL INTEGRADO DE ONCOLOGIA-Pesquisa Clínica ( Site 3007), Fortaleza, Ceara

Liga Norte Riograndense Contra o Câncer ( Site 3001), Natal., Rio Grande Do Norte

Irmandade da Santa Casa de Misericórdia de Porto Alegre ( Site 3003), Porto Alegre, Rio Grande Do Sul

Hospital Nossa Senhora da Conceição ( Site 3002), Porto Alegre, Rio Grande Do Sul

Fundação Pio XII - Hospital de Câncer de Barretos ( Site 3004), Barretos, Sao Paulo

Fundação Faculdade Regional de Medicina de São José do Rio Preto ( Site 3013), São José do Rio Preto, Sao Paulo

Instituto Nacional de Câncer - INCA ( Site 3000), Rio de Janeiro, Not set

Hospital Samaritano De Sao Paulo ( Site 3006), Sao Paulo, Not set

ICESP - INSTITUTO DO CÂNCER DO ESTADO DE SÃO PAULO ( Site 3005), Sao Paulo, Not set

Cross Cancer Institute ( Site 0105), Edmonton, Alberta

William Osler Health System ( Site 0101), Brampton, Ontario

Princess Margaret Cancer Centre ( Site 0102), Toronto, Ontario

Centre Hospitalier de l'Université de Montréal ( Site 0104), Montréal, Quebec

McGill University Health Centre ( Site 0100), Montréal, Quebec

Orlandi Oncologia-Oncology ( Site 3102), Santiago, Region M. De Santiago

FALP-UIDO ( Site 3100), Santiago, Region M. De Santiago

Pontificia Universidad Catolica de Chile ( Site 3104), Santiago, Region M. De Santiago

Bradfordhill-Clinical Area ( Site 3103), Santiago, Region M. De Santiago

ONCOCENTRO APYS ( Site 3105), Viña del Mar, Valparaiso

CIMCA ( Site 3300), San José, San Jose

ICIMED ( Site 3301), San Jose, Not set

Masarykuv onkologicky ustav-Klinika komplexni onkologicke pece ( Site 0700), Brno, Brno-mesto

Nemocnice AGEL Ostrava - Vitkovice a.s.-Plicni odd ( Site 0702), Ostrava, Ostrava Mesto

Fakultni nemocnice Olomouc-Klinika plicnich nemoci a tuberkulozy ( Site 0701), Olomouc, Not set

Vseobecna fakultni nemocnice v Praze ( Site 0703), Praha 2, Not set

Rigshospitalet ( Site 0801), Copenhagen, Hovedstaden

Odense Universitetshospital ( Site 0800), Odense C, Syddanmark

North Estonia Medical Centre Foundation-Chemotherapy ( Site 0901), Tallinn, Harjumaa

Tartu University Hospital-Radiotherapy and oncology ( Site 0900), Tartu, Tartumaa

Tampereen yliopistollinen sairaala-Oncology ( Site 1001), Tampere, Pirkanmaa

Vaasan Keskussairaala-Department of Clinical Oncology ( Site 1004), Vaasa, Pohjanmaa

Oulun yliopistollinen sairaala-Oncology and Hematology ( Site 1003), Oulu, Pohjois-Pohjanmaa

Turku University Hospital-The Department of Pulmonary Medicine ( Site 1000), Turku, Varsinais-Suomi

Nouvel Hôpital Civil (NHC)-Service de pneumologie ( Site 1100), Strasbourg, Alsace

CHU Bordeaux Haut-Leveque ( Site 1106), Pessac, Aquitaine

Assistance Publique Hôpitaux de Marseille - Hôpital Nord ( Site 1108), Marseille, Bouches-du-Rhone

Centre Hospitalier Universitaire de Caen - Hôpital Côte de Nacre ( Site 1107), Caen, Calvados

Hôpital Arnaud de Villeneuve - CHU Montpellier ( Site 1102), Montpellier, Herault

Institut de Cancérologie de l'Ouest ( Site 1101), ANGERS cedex 02, Maine-et-Loire

CHU GABRIEL MONTPIED ( Site 1105), Clermont-Ferrand, Puy-de-Dome

Hopitaux Universitaires Paris Centre-Hopital Cochin ( Site 1104), Paris, Not set

Klinikum Esslingen-Klinik für Kardiologie und Pneumologie ( Site 1201), Esslingen, Baden-Wurttemberg

Asklepios Klinik Gauting GmbH-Oncology ( Site 1209), Gauting, Bayern

Klinikverbund Allgäu gGmbH ( Site 1205), Kempten, Bayern

Universitaetsklinikum Regensburg ( Site 1204), Regensburg, Bayern

Augusta-Kranken-Anstalt ( Site 1213), Bochum, Nordrhein-Westfalen

Gemeinschaftspraxis für Hämatologie und Onkologie Münster ( Site 1202), Münster, Nordrhein-Westfalen

Brüderkrankenhaus St. Josef Paderborn-Klinik für Hämatologie und Onkologie ( Site 1214), Paderborn, Nordrhein-Westfalen

SRH Wald-Klinikum Gera-Lungenkrebszentrum ( Site 1200), Gera, Thuringen

Helios Klinikum Emil von Behring Berlin-Zehlendorf-Lungenklinik Heckeshorn ( Site 1208), Berlin, Not set

Errikos Dunant Hospital Center-Fourth Department of Oncology and Clinical Trials Unit ( Site 1301), Athens, Attiki

THORACIC GENERAL HOSPITAL OF ATHENS "I SOTIRIA"-3rd Dept of Internal Medicine and Laboratory, Oncol ( Site 1300), Athens, Attiki

European Interbalkan Medical Center-Oncology Department ( Site 1302), Thessaloniki, Not set

Bacs-Kiskun Varmegyei Oktatokorhaz-Onkoradiologiai Kozpont ( Site 1401), Kecskemét, Bacs-Kiskun

Pécsi Tudományegyetem Klinikai Központ-Onkoterápiás Intézet ( Site 1402), Pecs, Baranya

Gyor-Moson-Sopron Varmegyei Petz Aladar Egyetemi Oktato Korhaz - Pulmonologia Osztaly ( Site 1404), Gyor, Gyor-Moson-Sopron

Reformatus Pulmonologiai Centrum ( Site 1405), Törökbálint, Pest

Somogy Varmegyei Kaposi Mor Oktato Korhaz -Onkologiai Kozpont ( Site 1407), Kaposvár, Somogy

Tallaght University Hospital ( Site 3903), Dublin, Not set

CRO-IRCCS-Clinical Oncology ( Site 1510), Aviano, Friuli-Venezia Giulia

P.O. "S. Maria della Misericordia" Azienda Sanitaria Univers-Oncology Department ( Site 1506), Udine, Friuli-Venezia Giulia

Fondazione IRCCS Istituto Nazionale dei Tumori-Struttura Complessa Oncologia Medica 1 ( Site 1504), Milan, Lombardia

ASST Grande Ospedale Metropolitano Niguarda-Oncologia Falck ( Site 1511), Milan, Milano

A.O.R.N. Ospedale dei Colli - Monaldi V.-U.O.C Pneumologia Oncologica DH PNL ONC ( Site 1508), Naples, Napoli

Instituto Tumori Giovanni Paolo II-SSD Oncologia Medica per la Patologia Toracica ( Site 1507), Bari, Puglia

POLICLINICO "G. RODOLICO"-UOC Oncologia Medica ( Site 1503), Catania, Sicilia

AO Santa Maria della Misericordia-Oncology Department ( Site 1501), Perugia, Umbria

Azienda Ospedaliera Santa Croce e Carle ( Site 1500), Cuneo, Not set

Azienda Ospedaliero Universitaria Maggiore della Carità ( Site 1502), Novara, Not set

National Cancer Center Hospital East ( Site 3800), Kashiwa, Chiba

St. Marianna University Hospital ( Site 3802), Kawasaki, Kanagawa

Kanagawa Cancer Center ( Site 3801), Yokohama, Kanagawa

Kansai Medical University Hospital ( Site 3806), Hirakata, Osaka

Kindai University Hospital ( Site 3803), Osakasayama, Osaka

Hiroshima University Hospital ( Site 3804), Hiroshima, Not set

Chungbuk National University Hospital-Internal medicine ( Site 0402), Cheongju-si, Chungbuk

National Cancer Center-Lung Cancer Center ( Site 0403), Goyang-si, Kyonggi-do

Seoul National University Bundang Hospital-Medical Oncology ( Site 0404), Seongnam, Kyonggi-do

The Catholic University Of Korea St. Vincent's Hospital-Medical Oncology ( Site 0406), Suwon-si, Kyonggi-do

Keimyung University Dongsan Hospital CRC room 1 ( Site 0407), Daegu, Taegu-Kwangyokshi

Seoul National University Hospital ( Site 0400), Seoul, Not set

Asan Medical Center-Department of Oncology ( Site 0405), Seoul, Not set

Samsung Medical Center ( Site 0401), Seoul, Not set

RIGA EAST UNIVERSITY HOSPITAL ,Oncology Centre of Latvia ( Site 1600), Riga, Not set

Hospital of Lithuanian University of Health Sciences Kauno klinikos-Pulmonology ( Site 1701), Kaunas, Kauno Apskritis

National Cancer Institute-Department of Thoracic Surgery and Oncology ( Site 1700), Vilnius, Vilniaus Miestas

University Malaya Medical Centre ( Site 3502), Lembah Pantai, Kuala Lumpur

National Cancer Institute-Radiotherapy and Oncology ( Site 3506), Putrajaya, Kuala Lumpur

Hospital Tengku Ampuan Afzan ( Site 3504), Kuantan, Pahang

Hospital Pulau Pinang ( Site 3505), George Town, Pulau Pinang

Sarawak General Hospital ( Site 3500), Kuching, Sarawak

CIO - Centro de Inmuno-Oncología de Occidente ( Site 3403), Guadalajara, Jalisco

Hospital Universitario "Dr. Jose Eleuterio Gonzalez"-Hematologia and Oncologia ( Site 3408), Monterrey, Nuevo Leon

Unidad de Mastologia Avanzada de Chihuahua S.A de C.V ( Site 3402), Chihuahua, Not set

Mediadvance Clinical ( Site 3404), Chihuahua, Not set

Oaxaca Site Management Organization S.C. ( Site 3407), Oaxaca, Not set

Centro de Investigacion Clinica de Oaxaca ( Site 3401), Oaxaca, Not set

New Zealand Clinical Research (Christchurch) ( Site 0300), Christchurch, Canterbury

Harbour Cancer & Wellness ( Site 0301), Auckland, Not set

Akershus Universitetssykehus-Avdeling for lungesykdommer ( Site 1900), Lørenskog, Akershus

Drammen Sykehus, Vestre Viken HF ( Site 1903), Drammen, Buskerud

Stavanger Universitetssykehus ( Site 1901), Stavanger, Rogaland

Metro Davao Medical and Research Center ( Site 3602), Davao City, Davao Del Sur

ST. LUKE'S MEDICAL CENTER ( Site 3606), Quezon City, National Capital Region

CARDINAL SANTOS MEDICAL CENTER-Research Room ( Site 3601), San Juan City, Metro Manila, National Capital Region

Centrum Onkologii im. Prof. Franciszka Lukaszczyka-Ambulatorium Chemioterapii ( Site 2003), Bydgoszcz, Kujawsko-pomorskie

Krakowski Szpital Specjalistyczny im. Jana Pawła II-Oddział Kliniczny Chirurgii Klatki Piersiowej i ( Site 2011), Krakow, Malopolskie

Narodowy Instytut Onkologii im. Marii Sklodowskiej-Curie - P-Klinika Nowotworow Pluca i Klatki Pier ( Site 2000), Warszawa, Mazowieckie

Wojewodzki Szpital im. Sw. Ojca Pio w Przemyslu ( Site 2001), Przemysl, Podkarpackie

Bialostockie Centrum Onkologii ( Site 2005), Bialystok, Podlaskie

Uniwersyteckie Centrum Kliniczne ( Site 2013), Gdansk, Pomorskie

Warmińsko - Mazurskie Centrum Chorób Płuc w Olsztynie-Oddzial Onkologii z Pododdzialem Chemioterapii ( Site 2008), Olsztyn, Warminsko-mazurskie

Wielkopolskie Centrum Pulmonologii i Torakochirurgii-Oddzial Onkologii Klinicznej z Pododdzialem Dz ( Site 2002), Poznan, Wielkopolskie

Unidade Local de Saude de Santa Maria - Hospital Pulido Valente ( Site 2703), Lisbon, Lisboa

Instituto Português de Oncologia do Porto Francisco Gentil, EPE ( Site 2702), Porto, Not set

Fakultna nemocnica s poliklinikou F.D.Roosevelta Banska Bystrica ( Site 2202), Banska Bystrica, Banskobystricky Kraj

Univerzitná nemocnica Bratislava - Nemocnica Ružinov ( Site 2201), Bratislava, Bratislavsky Kraj

Institut Català d'Oncologia - L'Hospitalet-Medical Oncology ( Site 2401), L'Hospitalet de Llobregat, Barcelona

HOSPITAL UNIVERSITARIO PUERTA DE HIERRO MAJADAHONDA-Medical Oncology ( Site 2403), Majadahonda, Madrid, Comunidad De

HOSPITAL UNIVERSITARIO QUIRONSALUD MADRID-ONCOLOGIA MEDICA ( Site 2402), Pozuelo de Alarcon, Madrid

Hospital Quirón Málaga ( Site 2405), Málaga, Malaga

Hospital Universitari Vall d'Hebron-Departamento de Oncologia- VHIO ( Site 2400), Barcelona, Not set

Hospital Universitario Virgen Macarena-Unidad de Investigación Oncológica ( Site 2404), Sevilla, Not set

National Taiwan University Cancer Center (NTUCC) ( Site 0500), Taipei City, Taipei

Changhua Christian Hospital ( Site 0504), Changhua, Not set

National Taiwan University Hospital - Hsinchu branch ( Site 0501), Hsinchu, Not set

Taichung Veterans General Hospital-Chest ( Site 0503), Taichung, Not set

National Cheng Kung University Hospital-Clinical Trial Center ( Site 0505), Tainan, Not set

National Taiwan University Hospital-Oncology ( Site 0506), Taipei, Not set

Taipei Medical University Hospital ( Site 0502), Taipei, Not set

Medipol Mega Universite Hastanesi-oncology ( Site 2105), Stanbul, Istanbul

Ege Universitesi Hastanesi-Chest Diseases Department ( Site 2107), Bornova, Izmir

Hacettepe Universite Hastaneleri-oncology hospital ( Site 2100), Ankara, Not set

Memorial Ankara Hastanesi-Medical Oncology ( Site 2103), Ankara, Not set

Liv Hospital Ankara-Oncology ( Site 2104), Ankara, Not set

Ankara Bilkent Şehir Hastanesi-Medical Oncology ( Site 2101), Ankara, Not set

TC Saglik Bakanligi Goztepe Prof. Dr. Suleyman Yalcin Sehir Hastanesi-oncology ( Site 2102), Istanbul, Not set

Conditions: Non-small Cell Lung Cancer

Learn More ›

A Study of Local Ablative Therapy (LAT) in People With Non-Small Cell Lung Cancer (NSCLC)

NCT05429320

Recruiting

The purpose of this study is to see whether receiving local ablative therapy (LAT) when minimal residual disease/MRD levels are rising can reduce MRD levels and control metastatic non-small cell lung cancer/NSCLC longer compared to systemic therapy.

Gender:

ALL

Ages:

18 years and above

Trial Updated:

08/13/2025

Locations: Hartford Healthcare ALLIANCE (Data collection only), Hartford, Connecticut +8 locations

Conditions: Non-small Cell Lung Cancer, Metastatic Non Small Cell Lung Cancer, Nsclc, NSCLC Stage IV, Minimal Residual Disease, Non Small Cell Lung Cancer Metastatic

Learn More ›

A Study of MK-1084 Plus Pembrolizumab (MK-3475) in Participants With KRAS G12C Mutant Non-small Cell Lung Cancer (NSCLC) With Programmed Cell Death Ligand 1 (PD-L1) Tumor Proportion Score (TPS) ≥50% (MK-1084-004/KANDLELIT-004)

NCT06345729

Recruiting

This is a study evaluating the efficacy and safety of MK-1084 with pembrolizumab as first-line treatment in participants with locally advanced or metastatic non-small cell lung cancer (NSCLC) with identified Kirsten rat sarcoma viral oncogene homolog G12C (KRAS G12C) mutation and programmed cell death ligand 1 (PD-L1) tumor proportion score (TPS) ≥50%. There are two primary study hypotheses: Hypothesis 1: Combination of MK-1084 and pembrolizumab is superior to placebo plus pembrolizumab with re... Read More

Gender:

ALL

Ages:

18 years and above

Trial Updated:

08/12/2025

Locations: CBCC Global Research, Inc. ( Site 0123), Bakersfield, California +184 locations

CBCC Global Research, Inc. ( Site 0123), Bakersfield, California

Beverly Hills Cancer Center ( Site 0116), Beverly Hills, California

Mount Sinai Cancer Center ( Site 0137), Miami Beach, Florida

Orchard Healthcare Research Inc. ( Site 0115), Skokie, Illinois

Truman Medical Center ( Site 0126), Kansas City, Missouri

Cox Medical Center North ( Site 0133), Springfield, Missouri

St. Vincent Frontier Cancer Center-Research ( Site 0105), Billings, Montana

Atlantic Health System Morristown Medical Center ( Site 0121), Morristown, New Jersey

New York Oncology Hematology, P.C. ( Site 0132), Albany, New York

University of Cincinnati Medical Center-University of Cincinnati Cancer Center ( Site 0103), Cincinnati, Ohio

Kettering Health Main Campus-Kettering Health Cancer Center ( Site 0106), Kettering, Ohio

Oncology Consultants P.A. ( Site 0113), Houston, Texas

Circuit Clinical/SSM Health Dean Medical Group ( Site 0129), Madison, Wisconsin

AUSTRAL MEDICAL CENTER ( Site 0302), Caba, Buenos Aires

Centro Oncologico Korben ( Site 0304), Caba, Buenos Aires

Instituto de Investigaciones Clínicas Mar del Plata ( Site 0300), Mar del Plata, Buenos Aires

Fundacion Estudios Clinicos ( Site 0306), Rosario, Santa Fe

Sanatorio Parque ( Site 0301), Rosario, Santa Fe

Chris O'Brien Lifehouse ( Site 3000), Camperdown, New South Wales

Frankston Hospital ( Site 3002), Frankston, Victoria

One Clinical Research ( Site 3001), Nedlands, Western Australia

Medizinische Universität Graz-Klinische Abteilung für Pulmonologie ( Site 2401), Graz, Steiermark

Klinik Floridsdorf-Abteilung für Innere Medizin und Pneumologie ( Site 2400), Wien, Not set

Hospital Mario Penna ( Site 0436), Belo Horizonte, Minas Gerais

Hospital de Câncer de Recife ( Site 0447), Recife, Pernambuco

Oncoclínica Oncologistas Associados ( Site 0441), Terezina, Piaui

Liga Norte Riograndense Contra o Câncer ( Site 0439), Natal., Rio Grande Do Norte

Irmandade da Santa Casa de Misericórdia de Porto Alegre-Centro Multidisciplinar de Pesquisa Clínica ( Site 0435), Porto Alegre, Rio Grande Do Sul

Fundação Pio XII - Hospital de Câncer de Barretos-Unidade de Pesquisa Clínica ( Site 0437), Barretos., Sao Paulo

Instituto Nacional de Câncer - INCA ( Site 0446), Rio de Janeiro, Not set

Americas ( Site 0431), Rio de Janeiro, Not set

MBAL Uni Hospital-Department of Medical Oncology ( Site 1000), Panagyurishte, Pazardzhik

MHAT - Heart and Brain ( Site 1006), Pleven, Not set

CancerCare Manitoba ( Site 0210), Winnipeg, Manitoba

Hamilton Health Sciences-Juravinski Cancer Centre ( Site 0205), Hamilton, Ontario

Sunnybrook Research Institute ( Site 0206), Toronto, Ontario

St. Marys Hospital Center ( Site 0204), Montreal, Quebec

Centre integre universitaire de sante et de services sociaux de la Mauricie-et-du-centre-du-quebec ( Site 0207), Trois-Rivières, Quebec

Clinica Universidad Catolica del Maule-Oncology ( Site 0500), Talca, Maule

Orlandi Oncologia-Oncology ( Site 0503), Santiago, Region M. De Santiago

FALP-UIDO ( Site 0501), Santiago, Region M. De Santiago

Centro de Oncología de Precisión-Oncology ( Site 0502), Santiago, Region M. De Santiago

Bradfordhill-Clinical Area ( Site 0504), Santiago, Region M. De Santiago

Anhui Provincial Cancer Hospital ( Site 3136), Hefei, Anhui

Beijing Cancer hospital ( Site 3133), Beijing, Beijing

Beijing Cancer hospital ( Site 3134), Beijing, Beijing

Beijing Peking Union Medical College Hospital-pneumology department ( Site 3102), Beijing, Beijing

Beijing Chest Hospital,Capital Medical University ( Site 3104), Beijing, Beijing

Chongqing University Cancer Hospital ( Site 3119), Chongqing, Chongqing

Army Medical Center of People's Liberation Army ( Site 3142), Chongqing, Chongqing

Fujian Cancer Hospital ( Site 3127), Fuzhou, Fujian

The First Affiliated hospital of Xiamen University ( Site 3148), Xiamen, Fujian

The First Affiliated Hospital of Guangzhou Medical University ( Site 3108), Guangzhou, Guangdong

Southern Medical University Nanfang Hospital ( Site 3128), Guangzhou, Guangdong

Sun Yat-sen University Cancer Center ( Site 3137), Guangzhou, Guangdong

Harbin Medical University Cancer Hospital ( Site 3123), Harbin, Heilongjiang

JIAMUSI TUBERCULOSIS HOSPITAL(CANCER HOSPITAL) ( Site 3124), Jiamusi, Heilongjiang

Henan Cancer Hospital ( Site 3149), Zhengzhou, Henan

Tongji Hospital Tongji Medical,Science & Technology ( Site 3113), Wuhan, Hubei

Hubei Cancer Hospital ( Site 3126), Wuhan, Hubei

The Second Xiangya Hospital of Central South University ( Site 3130), Changsha, Hunan

Hunan Cancer Hospital ( Site 3141), Changsha, Hunan

Nanjing Gulou Hospital ( Site 3122), Nanjing, Jiangsu

Nanjing First Hospital ( Site 3154), Nanjing, Jiangsu

The First Affiliated Hospital of Soochow University ( Site 3146), Suzhou, Jiangsu

Affiliated Hospital of Jiangnan University(Wuxi Fourth People's Hospital ) ( Site 3155), Wuxi City, Jiangsu

The Second Affiliated Hospital of Nanchang University ( Site 3139), Nanchang, Jiangxi

The First affiliated hospital of Nanchang University (Xianghu campus) ( Site 3138), Nanchang, Jiangxi

Jilin Province Tumor Hospital ( Site 3107), Changchun, Jilin

The First Affiliated Hospital of Xi'an Jiaotong University ( Site 3150), Xian, Shaanxi

Shandong Cancer Hospital ( Site 3116), Jinan, Shandong

LinYi Cancer Hospital ( Site 3111), Linyi, Shandong

Shanghai Chest Hospital ( Site 3100), Shanghai, Shanghai

Fudan University Shanghai Cancer Center ( Site 3144), Shanghai, Shanghai

Zhongshan Hospital,Fudan University ( Site 3143), Shanghai, Shanghai

Shanxi Cancer Hospital ( Site 3131), Taiyuan, Shanxi

The Second Affiliated Hospital of Air Force Medical University ( Site 3117), Xian, Shanxi

The Second Affiliated Hospital of Air Force Medical University ( Site 3152), Xian, Shanxi

West China Hospital, Sichuan University ( Site 3140), Cheng Du, Sichuan

The Third People's Hospital of Chengdu (CDTPH) ( Site 3157), Chengdu, Sichuan

Sichuan Cancer hospital. ( Site 3109), Chengdu, Sichuan

The Second People's Hospital of Neijiang ( Site 3105), Neijiang, Sichuan

Xinjiang Medical University Cancer Hospital - Urumqi ( Site 3101), Urumqi, Xinjiang

Yunnan Province Cancer Hospital ( Site 3153), Kunming, Yunnan

The first Affiliated Hospital, Zhejiang University School of Medicine ( Site 3115), Hangzhou, Zhejiang

Sir Run Run Shaw Hospital of Zhejiang University School of Medicine ( Site 3121), Hangzhou, Zhejiang

Taizhou Hospital of Zhejiang Province ( Site 3145), Linhai, Zhejiang

The First Affiliated Hospital of Wenzhou Medical University ( Site 3151), Wenzhou, Zhejiang

Centre Hospitalier Universitaire Dijon Bourgogne - Hôpital François Mitterrand ( Site 1103), Dijon, Bourgogne

Hôpital Ambroise Paré-Department of Respiratory Diseases and Thoracic Oncology ( Site 1105), Boulogne-Billancourt, Ile-de-France

Clinique Teissier Groupe ( Site 1100), Valenciennes, Nord

Centre Jean Perrin - Centre Régional de Lutte contre le Cancer d'Auvergne-ONCOLOGY ( Site 1101), Clermont-Ferrand, Puy-de-Dome

Centre Hospitalier d'Avignon-Service d'Oncologie médicale et d'hématologie clinique ( Site 1104), Avignon, Vaucluse

High Technology Hospital Medcenter ( Site 1203), Batumi, Ajaria

Caucasus Medical Centre ( Site 1202), Tbilisi, Ajaria

American Hospital Network LLC ( Site 1208), Tbilisi, Not set

Todua Clinic, LLC ( Site 1204), Tbilisi, Not set

TSMU and Ingorokva High Medical Technology University Clinic LTD ( Site 1201), Tbilisi, Not set

New Hospitals ( Site 1200), Tbilisi, Not set

Cancer Research Centre. Mardaleishvili Medical Centre ( Site 1205), Tbilisi, Not set

Tbilisi Institute of Medicine ( Site 1206), Tbilisi, Not set

Marienhospital Stuttgart ( Site 1302), Stuttgart, Baden-Wurttemberg

Krankenhaus Bethanien ( Site 1303), Solingen, Nordrhein-Westfalen

UNIVERSITY HOSPITAL OF PATRAS-DIVISION OF ONCOLOGY ( Site 1402), Patras, Achaia

THORACIC GENERAL HOSPITAL OF ATHENS "I SOTIRIA"-3rd Dept of Internal Medicine and Laboratory, Oncol ( Site 1400), Athens, Attiki

University General Hospital of Larissa-Oncology Clinic ( Site 1403), Larissa, Thessalia

Agios Loukas Clinic ( Site 1404), Thessaloniki, Not set

G. Papanikolaou General Hospital-Pulmonary Clinic of Aristotle University of Thessaloniki ( Site 1405), Thessaloniki, Not set

Istituto Nazionale Tumori IRCCS Fondazione Pascale-Oncologia clinica sperimentale Toraco-Polmonare ( Site 1607), Napoli, Campania

Ospedale Santa Maria delle Croci ( Site 1606), Ravenna, Emilia-Romagna

CRO-IRCCS-Clinical Oncology ( Site 1605), Aviano, Friuli-Venezia Giulia

Fondazione Policlinico Universitario Agostino Gemelli IRCCS -Medical Oncology ( Site 1601), Roma, Lazio

Istituto Europeo di Oncologia IRCCS-Divisione di Oncologia Toracica ( Site 1604), Milano, Lombardia

Fondazione IRCCS Istituto Nazionale dei Tumori-Struttura Complessa Oncologia Medica 1 ( Site 1600), Milan, Lombardia

Istituto Nazionale Tumori Regina Elena-Oncologia Medica 2 ( Site 1609), Rome, Roma

Azienda USL Toscana Nord Ovest_Ospedale Civile di Livorno-UOC Oncologia Medica Livorno ( Site 1608), Livorno, Toscana

Istituto Oncologico Veneto IRCCS-Oncologia 2 ( Site 1603), Padova, Not set

Nagoya University Hospital ( Site 3309), Nagoya, Aichi

Fujita Health University Hospital ( Site 3310), Toyoake, Aichi

National Hospital Organization Shikoku Cancer Center ( Site 3315), Matsuyam, Ehime

National Hospital Organization Kyushu Cancer Center ( Site 3316), Fukuoka,, Fukuoka

Kurume University Hospital ( Site 3317), Kurume, Fukuoka

Gunma Prefectural Cancer Center ( Site 3302), Ota, Gunma

Kanazawa University Hospital ( Site 3308), Kanazawa, Ishikawa

St. Marianna University Hospital ( Site 3320), Kawasaki, Kanagawa

Matsusaka Municipal Hospital ( Site 3311), Matsusaka, Mie

Miyagi Cancer Center ( Site 3301), Natori, Miyagi

Sendai Kousei Hospital ( Site 3300), Sendai, Miyagi

Kansai Medical University Hospital ( Site 3312), Hirakata, Osaka

Osaka Medical and Pharmaceutical University Hospital ( Site 3313), Takatsuki, Osaka

Nippon Medical School Hospital ( Site 3306), Bunkyo, Tokyo

Toho University Omori Medical Center ( Site 3319), Ota, Tokyo

Tokyo Medical University Hospital ( Site 3307), Shinjuku, Tokyo

National Center for Global Health and Medicine ( Site 3305), Shinjuku, Tokyo

Chiba University Hospital ( Site 3322), Chiba, Not set

Hiroshima City Hiroshima Citizens Hospital ( Site 3314), Hiroshima, Not set

Saiseikai Kumamoto Hospital ( Site 3318), Kumamoto, Not set

Osaka Metropolitan University Hospital ( Site 3321), Osaka, Not set

The Catholic University of Korea, Incheon St. Mary's Hospital ( Site 3606), Bupyeong-gu, Incheon

Chonnam National University Hwasun Hospital-Pulmonology ( Site 3604), Hwasun, Jeonranamdo

The Catholic University Of Korea St. Vincent's Hospital-Medical Oncology ( Site 3600), Suwon-si, Kyonggi-do

Pusan National University Yangsan Hospital-Lung Cancer Clinic ( Site 3603), Yangsan, Kyongsangnam-do

Chungnam national university hospital ( Site 3602), Jung-gu, Taejon-Kwangyokshi

Kyung Hee University Hospital ( Site 3605), Seoul, Not set

Korea University Guro Hospital ( Site 3601), Seoul, Not set

Arké SMO S.A. de C.V. ( Site 0602), Mexico, Distrito Federal

Oaxaca Site Management Organization S.C. ( Site 0603), Oaxaca, Not set

Ziekenhuis St. Jansdal-Poli Longziekten ( Site 1701), Harderwijk, Gelderland

Isala, locatie Zwolle-Poli Longziekten ( Site 1700), Zwolle, Overijssel

Universitair Medisch Centrum Utrecht ( Site 1704), Utrecht, Not set

Auckland City Hospital ( Site 3400), Auckland, Not set

Lung Center of the Philippines-Pulmonary, Critical Care and Sleep Medicine ( Site 3503), Quezon City, National Capital Region

Veterans Memorial Medical Center-Section of Oncology ( Site 3505), Quezon City, National Capital Region

Szpital Specjalistyczny im. Henryka Klimontowicza ( Site 1801), Gorlice, Malopolskie

Pratia MCM Krakow ( Site 1808), Krakow, Malopolskie

Narodowy Instytut Onkologii im. Marii Sklodowskiej-Curie - P-Klinika Nowotworow Pluca i Klatki Pier ( Site 1800), Warszawa, Mazowieckie

Wojewodzki Szpital im. Sw. Ojca Pio w Przemyslu ( Site 1804), Przemysl, Podkarpackie

Centrul de Oncologie Sfantul Nectarie-Medical ( Site 1994), Craiova, Dolj

Cabinet Medical Oncomed ( Site 1998), Timișoara, Timis

SC ONCO CARD SRL ( Site 1995), Brasov, Not set

Institutul Oncologic Cluj-Oncologie Medicala ( Site 1999), Cluj, Not set

Sigmedical Services SRL ( Site 1997), Suceava, Not set

Hospital Insular de Gran Canaria-Oncology ( Site 2019), Las Palmas de Gran Canaria, Las Palmas

HOSPITAL GENERAL UNIVERSITARIO GREGORIO MARAÑON-ONCOLOGY ( Site 2012), Madrid, Madrid, Comunidad De

H.R.U Málaga - Hospital General-Oncology ( Site 2014), Málaga, Malaga

Hospital Universitari Vall d Hebron ( Site 2010), Barcelona, Not set

Hospital Universitario Fundación Jiménez Díaz-Oncology & Hematology ( Site 2017), Madrid, Not set

Hospital Universitario Virgen Macarena-Unidad de Investigación Oncológica ( Site 2015), Sevilla, Not set

Adana Medical Park Seyhan Hastanesi-Medikal Onkoloji ( Site 2107), Adana, Not set

SBU GULHANE EGITIM VE ARASTIRMA HASTANESI Onkoloji ( Site 2104), Ankara, Not set

Hacettepe Universite Hastaneleri-oncology hospital ( Site 2101), Ankara, Not set

Memorial Ankara Hastanesi-Medical Oncology ( Site 2106), Ankara, Not set

Medipol Mega Universite Hastanesi-oncology ( Site 2105), Istanbul, Not set

TC Saglik Bakanligi Goztepe Prof. Dr. Suleyman Yalcin Sehir Hastanesi-oncology ( Site 2103), Istanbul, Not set

COMMUNAL NONPROFIT ENTERPRISE "CLINICAL CENTER OF ONCOLOGY, HEMATOLOGY, TRANSPLANTOLOGY AND PALLIATI ( Site 2209), Cherkasy, Cherkaska Oblast

Regional Municipal Non-profit Enterprise "Bukovinian Clinica-structural unit of the clinical trials ( Site 2210), Chernivtsi, Chernivetska Oblast

Medical Center "Mriya Med-Service"-Clinical Research Department ( Site 2215), Kryvyi Rih, Dnipropetrovska Oblast

Communal Non-Commercial Enterprise "Prykarpatski Clinical On-Surgery department #2 ( Site 2202), Ivano-Frankivsk, Ivano-Frankivska Oblast

Kirovohrad Regional Oncology Center-Chemotherapy department ( Site 2204), Kropyvnytskyi, Kirovohradska Oblast

Medical Center "MedOffice Group" ( Site 2219), Kiev, Kyivska Oblast

Municipal non-profit enterprise "Lviv Territorial Medical Union "Multidisciplinary Clinical Hospital ( Site 2217), Lviv, Lvivska Oblast

Rivne Regional Clinical Hospital ( Site 2205), Rivne, Rivnenska Oblast

ME RIVNE REGIONAL ANTITUMOR CENTER ( Site 2920), Rivne, Rivnenska Oblast

Communal Noncommercial Enterprise "Podillia Regional Oncolog-Cardiothoracic department ( Site 2211), Vinnytsia, Vinnytska Oblast

ME Volyn Regional Clinical Hospital of the Volyn Regional Council ( Site 2216), Lutsk, Volynska Oblast

Conditions: Non-small Cell Lung Cancer

Learn More ›

Neladalkib (NVL-655) for TKI-naive Patients With Advanced ALK-Positive NSCLC

NCT06765109

Recruiting

Multicenter, randomized, controlled, open-label, Phase 3 study designed to demonstrate that neladalkib (NVL-655) is superior to alectinib in prolonging progression-free survival (PFS) in patients with treatment-naïve, Anaplastic Lymphoma Kinase (ALK) positive, advanced Non-Small Cell Lung Cancer (NSCLC).

Gender:

ALL

Ages:

18 years and above

Trial Updated:

08/08/2025

Locations: Palo Verde Hematology Oncology, Glendale, Arizona +6 locations

Conditions: Non-small Cell Lung Cancer, Anaplastic Lymphoma Kinase-positive

Learn More ›

A Study of Multiple Therapies in Biomarker-Selected Patients With Resectable Stages IB-III Non-Small Cell Lung Cancer

NCT04302025

Recruiting

This trial will evaluate the efficacy and safety of various therapies in patients with Stage IB, IIA, IIB, IIIA, or selected IIIB resectable and untreated non-small cell lung cancer (NSCLC) tumors that meet protocol-specified biomarker criteria

Gender:

ALL

Ages:

18 years and above

Trial Updated:

08/08/2025

Locations: City of Hope Comprehensive Cancer Center, Duarte, California +38 locations

City of Hope Comprehensive Cancer Center, Duarte, California

City of Hope - Orange County Lennar Foundation Cancer Center, Irvine, California

USC Norris Cancer Center, Los Angeles, California

Cedars-Sinai Medical Center, Los Angeles, California

University of California Los Angeles - Jonsson Comprehensive Cancer Center, Los Angeles, California

The Center for Cancer Prevention and Treatment at St.Joseph Hospital of Orange, Orange, California

UC Davis Comprehensive Cancer Center, Sacramento, California

UCSF Helen Diller Family CCC, San Francisco, California

University of Colorado - Anschutz Medical Campus (University of Colorado Health Sciences Center), Aurora, Colorado

Yale Cancer Center, New Haven, Connecticut

MedStar Georgetown University Hospital (Lombardi Comprehensive Cancer Center), Washington, District of Columbia

Moffitt Cancer Center, Tampa, Florida

Northwestern University, Chicago, Illinois

Northwestern Medicine Cancer Center Kishwaukee, DeKalb, Illinois

Northwestern Medicine Cancer Center Delnor, Geneva, Illinois

Northwestern Medicine Cancer Center Warrenville, Warrenville, Illinois

Boston Medical Center, Boston, Massachusetts

Dana-Farber Cancer Institute, Boston, Massachusetts

University of Michigan, Ann Arbor, Michigan

Karmanos Cancer Institute - Farmington Hills/Weisberg Cancer Treatment Center, Farmington Hills, Michigan

Mayo Clinic, Rochester, Minnesota

Ellis Fischel Cancer Center, Columbia, Missouri

Siteman Cancer Center - Washington University Medical Campus, Saint Louis, Missouri

Dartmouth Hitchcock Medical Center, Lebanon, New Hampshire

Laura and ISAAC Perlmutter Cancer Center at NYU Langone., New York, New York

Columbia University Medical Center, New York, New York

Memorial Sloan Kettering Cancer Center, New York, New York

University Hospitals Cleveland Medical Center, Cleveland, Ohio

Ohio State University, Columbus, Ohio

AHN Cancer Institute ? Allegheny General Hospital, Pittsburgh, Pennsylvania

Baptist Clinical Research Institute, Memphis, Tennessee

Tennessee Oncology - Nashville, Nashville, Tennessee

Kelsey Seybold Clnic, Houston, Texas

University of Texas MD Anderson Cancer Center, Houston, Texas

Baylor College of Medicine, Houston, Texas

Lumi Research, Kingwood, Texas

Virginia Cancer Specialists (Fairfax) - USOR, Fairfax, Virginia

Seattle Cancer Care Alliance, Seattle, Washington

Conditions: Non-small Cell Lung Cancer

Learn More ›

A Phase 2 Study of Zanidatamab in Patients With HER2-expressing Tumors

NCT06695845

Recruiting

The purpose of this study is to evaluate the efficacy and safety of zanidatamab for the treatment of participants with previously treated solid tumors that have Human Epidermal Growth Factor Receptor 2 (HER2) Immunohistochemistry (IHC) 3+ overexpression.

Gender:

ALL

Ages:

18 years and above

Trial Updated:

08/07/2025

Locations: Arizona Oncology Associates, PC - NAHOA, Prescott, Arizona +20 locations

Conditions: Breast Cancer, Gastric Cancer, Esophageal Cancer, Gastroesophageal Cancer, Colorectal Cancer, Endometrial Cancer, Non-small Cell Lung Cancer, Ovarian Cancer, Urothelial Carcinoma, Salivary Gland Cancer, Pancreatic Cancer, HER-2 Protein Overexpression

Learn More ›

Neoadjuvant and Adjuvant Treatment in Resectable Non-small Cell Lung Cancer

NCT05061550

Recruiting

The study is intended to assess the safety and efficacy of perioperative treatment with Durvalumab in combination with Oleclumab, Monalizumab, or AZD0171 and platinum doublet chemotherapy (CTX); or Volrustomig or Rilvegostomig in combination with CTX; or Datopotamab deruxtecan (Dato-DXd) in combination with Durvalumab or Rilvegostomig and single agent platinum chemotherapy in participants with resectable, early-stage non-small cell lung cancer.

Gender:

ALL

Ages:

Between 18 years and 95 years

Trial Updated:

08/07/2025

Locations: Research Site, Little Rock, Arkansas +97 locations

Research Site, Little Rock, Arkansas

Research Site, Los Angeles, California

Research Site, Oakland, California

Research Site, New Haven, Connecticut

Research Site, Stuart, Florida

Research Site, Gainesville, Georgia

Research Site, Chicago, Illinois

Research Site, Baltimore, Maryland

Research Site, Boston, Massachusetts

Research Site, Saint Louis Park, Minnesota

Research Site, Omaha, Nebraska

Research Site, Buffalo, New York

Research Site, Cleveland, Ohio

Research Site, Pittsburgh, Pennsylvania

Research Site, Chattanooga, Tennessee

Research Site, Memphis, Tennessee

Research Site, Nashville, Tennessee

Research Site, Houston, Texas

Research Site, Fairfax, Virginia

Research Site, Seattle, Washington

Research Site, Charleroi, Not set

Research Site, Gent, Not set

Research Site, Leuven, Not set

Research Site, Roeselare, Not set

Research Site, Edmonton, Alberta

Research Site, Winnipeg, Manitoba

Research Site, Montréal, Quebec

Research Site, Avignon Cedex, Not set

Research Site, Bobigny, Not set

Research Site, Bordeaux, Not set

Research Site, Limoges, Not set

Research Site, Rennes Cedex, Not set

Research Site, Rouen, Not set

Research Site, Suresnes, Not set

Research Site, Toulon, Not set

Research Site, Kecskemét, Not set

Research Site, Székesfehérvár, Not set

Research Site, Tatabánya, Not set

Research Site, Törökbálint, Not set

Research Site, Dublin 7, Not set

Research Site, Dublin 8, Not set

Research Site, Dublin, Not set

Research Site, Galway, Not set

Research Site, Aviano, Not set

Research Site, Brescia, Not set

Research Site, Catanzaro, Not set

Research Site, Firenze, Not set

Research Site, Genova, Not set

Research Site, Meldola, Not set

Research Site, Milano, Not set

Research Site, Monza, Not set

Research Site, Padova, Not set

Research Site, Perugia, Not set

Research Site, Pisa, Not set

Research Site, Roma, Not set

Research Site, Rozzano, Not set

Research Site, Busan, Not set

Research Site, Chungcheongbuk-do, Not set

Research Site, Seongnam-si, Not set

Research Site, Seoul, Not set

Research Site, Suwon, Not set

Research Site, Lisboa, Not set

Research Site, Lisbon, Not set

Research Site, Porto, Not set

Research Site, A Coruña, Not set

Research Site, Alicante, Not set

Research Site, Barcelona, Not set

Research Site, Córdoba, Not set

Research Site, Madrid, Not set

Research Site, Majadahonda, Not set

Research Site, Málaga, Not set

Research Site, Reus, Not set

Research Site, Sevilla, Not set

Research Site, Terrassa, Not set

Research Site, Valencia, Not set

Research Site, Liuying, Not set

Research Site, New Taipei, Not set

Research Site, Tainan City, Not set

Research Site, Taipei, Not set

Research Site, Ankara, Not set

Research Site, Istanbul, Not set

Research Site, Izmir, Not set

Conditions: Non-small Cell Lung Cancer

Learn More ›

A Study of Valemetostat Tosylate Plus Pembrolizumab Versus Pembrolizumab Alone in First-Line NSCLC Without Actionable Genomic Alterations

NCT06644768

Recruiting

This study will compare Valemetostat Tosylate Plus Pembrolizumab vs Pembrolizumab Alone in First-line NSCLC Without Actionable Genomic Alterations

Gender:

ALL

Ages:

18 years and above

Trial Updated:

08/07/2025

Locations: University of California San Diego (Ucsd)-Moores Cancer Center, La Jolla, California +44 locations

University of California San Diego (Ucsd)-Moores Cancer Center, La Jolla, California

California Research Institute, Los Angeles, California

Valkyrie Clinical Trials, Los Angeles, California

Mayo Clinic Hospital, Jacksonville, Florida

BRCR Global, Plantation, Florida

University of Kentucky Medical Center, Lexington, Kentucky

Pikeville Medical Center, Pikeville, Kentucky

Mayo Clinic - Rochester, Rochester, Minnesota

Montefiore Medical Center, Bronx, New York

Columbia University Irving Medical Center, New York, New York

Thomas Jefferson University, Sidney Kimmel Cancer Center, Philadelphia, Pennsylvania

Virginia Cancer Specialist, Fairfax, Virginia

Instituto Alexander Fleming, Buenos Aires, Not set

Hospital Italiano de Buenos Aires, Ciudad Autonoma de Buenos Aires, Not set

Sanatorio Allende, Cordoba, Not set

Fundacion Ars Medica, N Salvador De Jujuy, Not set

Centro de Investigacion Pergamino Sa, Pergamino, Not set

Instituto Medico de La Fundacion Estudios Clinicos, Rosario, Not set

Clinica Viedma S.A., Viedma, Not set

Centro de Pesquisas Clinica Reichow, Blumenau, Not set

Clínica de Neoplasias Litoral Ltda., ItajaĂ-, Not set

CINPAM Centro Integrado De Pesquisa Da Amazonia, Manaus, Not set

Liga Norte-Rio-Grandense Contra o Câncer, Natal, Not set

Hospital Nossa Senhora da Conceicao, Porto Alegre, Not set

Cepho - Centro de Estudos E Pesquisas de Hematologia E Oncologia, Santo Andre, Not set

Fundacao Faculdade Regional de Medicina de Sao Jose Do Rio Preto, Sao Jose Rio Preto, Not set

Jilin Cancer Hospital, Changchun, Not set

The First Hospital of Jilin University, Changchun, Not set

Chengdu Shang Jin Nan Fu Hospital, Chengdu, Not set

Sir Run Run Shaw Hospital, Zhejiang University, School of Medicine, Hangzhou, Not set

Harbin Medical University Cancer Hospital, Harbin, Not set

Jiamusi Cancer Hospital, Shanghai, Not set

Shanghai East Hospital, Shanghai, Not set

The First Hospital of China Medical University, Shenyang City, Not set

Tianjin Medical University Cancer Institute & Hospital, Tiyuan, Not set

Henan Cancer Hospital, Zhengzhou, Not set

Kyushu University Hospital, Fukuoka, Not set

National Cancer Center Hospital East, Kashiwa, Not set

Cancer Institute Hospital of JFCR, Koto-ku, Not set

NHO Nagoya Medical Center, Nagoya-shi, Not set

Kitasato University Hospital, Sagamihara-shi, Not set

Severance Hospital, Yonsei University Health System, Seoul, Not set

Samsung Medical Center, Seoul, Not set

Seoul National University Hospital, Seoul, Not set

The Catholic University of Korea, St. Vincent'S Hospital, Suwon-si, Not set

Conditions: Non-small Cell Lung Cancer, Lung Cancer

Learn More ›

Volrustomig Priming Regimens Exploratory Phase II Platform Study

NCT06448754

Recruiting

Purpose of this study is to assess the safety, tolerability, pharmacokinetics, immunogenicity, and antitumor activity of volrustomig in combination with other anticancer drugs in participants with specified solid tumors.

Gender:

ALL

Ages:

Between 18 years and 130 years

Trial Updated:

08/06/2025

Locations: Research Site, Los Angeles, California +75 locations

Research Site, Los Angeles, California

Research Site, Grand Junction, Colorado

Research Site, Wheat Ridge, Colorado

Research Site, Baltimore, Maryland

Research Site, Detroit, Michigan

Research Site, Chapel Hill, North Carolina

Research Site, Tacoma, Washington

Research Site, Montreal, Quebec

Research Site, Beijing, Not set

Research Site, Hangzhou, Not set

Research Site, Jinan, Not set

Research Site, Yantai, Not set

Research Site, Zhengzhou City, Not set

Research Site, Bois Guillaume, Not set

Research Site, Caen Cedex, Not set

Research Site, Créteil, Not set

Research Site, Dijon, Not set

Research Site, Montpellier, Not set

Research Site, Batumi, Not set

Research Site, Tbilisi, Not set

Research Site, Athens, Not set

Research Site, Elaiones, Not set

Research Site, Peiraias, Not set

Research Site, Thessaloniki, Not set

Research Site, Genoa, Not set

Research Site, Meldola, Not set

Research Site, Milano, Not set

Research Site, Napoli, Not set

Research Site, Orbassano, Not set

Research Site, Perugia, Not set

Research Site, Rozzano, Not set

Research Site, Udine, Not set

Research Site, Verona, Not set

Research Site, Seongnam, Not set

Research Site, Seoul, Not set

Research Site, Suwon, Not set

Research Site, Kuala Lumpur, Not set

Research Site, Kuching, Not set

Research Site, Perai, Not set

Research Site, Lisboa, Not set

Research Site, Porto, Not set

Research Site, Cluj-Napoca, Not set

Research Site, Craiova, Not set

Research Site, Floresti, Not set

Research Site, Belgrade, Not set

Research Site, Kragujevac, Not set

Research Site, Sremska Kamenica, Not set

Research Site, A Coruña, Not set

Research Site, Alcorcón, Not set

Research Site, Barcelona, Not set

Research Site, Madrid, Not set

Research Site, Málaga, Not set

Research Site, Pamplona, Not set

Research Site, Santander, Not set

Research Site, Santiago de Compostela, Not set

Research Site, Valencia, Not set

Research Site, Basel, Not set

Research Site, Genève 14, Not set

Research Site, Lausanne, Not set

Research Site, Winterthur, Not set

Research Site, Zürich, Not set

Research Site, Changhua City, Not set

Research Site, New Taipei, Not set

Research Site, Taipei City, Not set

Research Site, Taipei, Not set

Conditions: Non-small Cell Lung Cancer

Learn More ›

A Study to Learn About the Study Medicine Called PF-07799544 in People With Advanced Solid Tumors

NCT05538130

Recruiting

The purpose of this clinical trial is to learn the safety and effects of the study medicine (PF-07799544) administered as a single agent and in combination with other study medications in people with solid tumors. This study is seeking participants who have an advanced solid tumor for which the available treatments are no longer effective in controlling their cancer. All participants in this study will receive PF-07799544. PF-07799544 comes as a tablet to take by mouth daily (initially 2 times p... Read More

Gender:

ALL

Ages:

16 years and above

Trial Updated:

08/05/2025

Locations: Highlands Oncology Group, Fayetteville, Arkansas +47 locations

Highlands Oncology Group, Fayetteville, Arkansas

Highlands Oncology Group, Rogers, Arkansas

Highlands Oncology Group, PA, Springdale, Arkansas

The Angeles Clinic and Research Institute- A Cedars-Sinai Affiliate, Los Angeles, California

The Angeles Clinic and Research Institue, A Cedars-Sinai Affiliate (Emergency Back-up only), Santa Monica, California

Moffitt Cancer Center, Richard M. Shulze Family Foundation Outpatient Center, Tampa, Florida

Moffitt Cancer Center, Tampa, Florida

Moffitt McKinley Hospital, Tampa, Florida

Brigham and Women's Hospital, Boston, Massachusetts

Dana Farber Cancer Institute, Boston, Massachusetts

Dana-Farber Cancer Institute, Boston, Massachusetts

Brigitte Harris Cancer Pavilion, Detroit, Michigan

Henry Ford Hospital, Detroit, Michigan

MSK Basking Ridge., Basking Ridge, New Jersey

MSK Monmouth., Middletown, New Jersey

MSK Bergen., Montvale, New Jersey

Optum Medical Care, PC, Brewster, New York

MSK Commack., Commack, New York

MSK Westchester., Harrison, New York

Memorial Sloan Kettering Cancer Center 53rd street., New York, New York

Columbia University Irving Medical Center, New York, New York

Columbia University Medical Center - Neurological Institute of New York, New York, New York

CUIMC Research Pharmacy, New York, New York

Memorial Sloan Kettering Cancer Center - Main Campus, New York, New York

Brooklyn Radiation Oncology, PC, Richmond Hill, New York

MSK Nassau., Uniondale, New York

Clinical Research Alliance, Westbury, New York

Cleveland Clinic Taussig Cancer Center Investigational Pharmacy, Cleveland, Ohio

Cleveland Clinic Taussig Cancer Center, Cleveland, Ohio

Providence Cancer Institute Franz Clinic, Portland, Oregon

Providence Portland Medical Center, Portland, Oregon

Sarah Cannon Research Institute- Pharmacy, Nashville, Tennessee

SCRI Oncology Partners, Nashville, Tennessee

University of Texas MD Anderson Cancer Center, Houston, Texas

Fred Hutchinson Cancer Center, Seattle, Washington

University of Washington Medical Center, Seattle, Washington

Cross Cancer Institute, Edmonton, Alberta

The Ottawa Hospital - General Campus, Ottawa, Ontario

Sunnybrook Research Institute, Toronto, Ontario

Princess Margaret Cancer Centre, Toronto, Ontario

Jewish General Hospital, Montreal, Quebec

McGill University Health Centre, Montréal, Quebec

Centre intégré de cancérologie du CHU de Québec Université Laval, Hôpital de l'Enfant-Jésus, Quebec City, Quebec

Soroka Medical Center, Beer-Sheva, Hadarom

Rabin Medical Center, Petah Tikva, Hamerkaz

Sheba Medical Center, Ramat Gan, Hamerkaz

Sourasky Medical Center, Tel Aviv, Tell Abīb

Hadassah Medical Center, Jerusalem, Yerushalayim

Conditions: Melanoma, Glioma, Thyroid Cancer, Non-Small Cell Lung Cancer, Malignant Neoplasms, Brain Neoplasms, Colorectal Cancer

Learn More ›

A Study of the Pan-KRAS Inhibitor LY4066434 in Participants With KRAS Mutant Solid Tumors

NCT06607185

Recruiting

The main purpose of the study is to assess whether the study drug, LY4066434, is safe and tolerable when administered to participants with locally advanced or metastatic solid tumors with certain KRAS mutations. LY4066434 will be given alone or in combination with other treatments. The study will have 2 parts: monotherapy dose escalation and dose optimization. The study is expected to last up to approximately 5 years.

Gender:

ALL

Ages:

18 years and above

Trial Updated:

08/05/2025

Locations: University of Alabama at Birmingham, Birmingham, Alabama +54 locations

University of Alabama at Birmingham, Birmingham, Alabama

Mayo Clinic, Phoenix, Arizona

City of Hope, Duarte, California

University of California, Los Angeles (UCLA), Los Angeles, California

University of Colorado Denver, Denver, Colorado

Yale University School of Medicine - Yale Cancer Center, New Haven, Connecticut

The University of Chicago Medical Center (UCMC), Chicago, Illinois

Indiana University (IU), Indianapolis, Indiana

Massachusetts General Hospital, Boston, Massachusetts

Dana-Farber Cancer Institute, Boston, Massachusetts

Henry Ford Health System, Detriot, Michigan

South Texas Accelerated Research Therapeutics (START) Midwest, Grand Rapids, Michigan

Mayo Clinic - Rochester, Rochester, Minnesota

Columbia University, New York, New York

David H. Koch Center for Cancer Care at Memorial Sloan Kettering Cancer Center, New York, New York

Duke University Medical Center, Durham, North Carolina

Cleveland Clinic, Cleveland, Ohio

University of Oklahoma - Health Sciences Center, Oklahoma City, Oklahoma

University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania

SCRI Oncology Partners, Nashville, Tennessee

University of Texas Southwestern, Dallas, Texas

MD Anderson Cancer Center, Houston, Texas

South Texas Accelerated Research Therapeutics (START), San Antonio, Texas

Virginia Cancer Specialists, Fairfax, Virginia

Swedish Cancer Institute (SCI), Seattle, Washington

Universite Libre de Bruxelles (ULB) - Institut Jules Bordet, Brussels, Not set

Cliniques universitaires Saint-Luc, Brussels, Not set

University Hospital Gent, Gent, Not set

Cancer Institute & Hospital, Chinese Academy of Medical Sciences, Beijing, Not set

The First Affiliated Hospital, College of Medicine, Zhejiang University, Hangzhou, Not set

Shandong Province Tumor Hospital, Jinan, Not set

Shanghai East Hospital, Tongji University, Shanghai, Not set

Tianjin Medical University Cancer Institute & Hospital, Tianjin, Not set

Centre Leon Berard, Lyon, Not set

Institut Gustave Roussy, Villejuif cedex, Not set

Charite Universitaetsmedizin Berlin, Berlin, Not set

Krankenhaus Nordwest GmbH, Frankfurt, Not set

Asklepios Kliniken Hamburg GmbH - Asklepios Klinik Altona, Hamburg, Not set

SLK-Kliniken Heilbronn GmBH, Heilbronn, Not set

Universitaetsklinikum Wuerzburg, Wuerzburg, Not set

Centro Ricerche Cliniche di Verona s.r.l., Verona, Not set

National Cancer Center Hospital East, Chiba, Not set

Kyoto University Hospital, Kyoto, Not set

Shizuoka Cancer Center, Shizuoka, Not set

National Cancer Center Hospital, Tokyo, Not set

Cancer Institute Hospital of JFCR, Tokyo, Not set

Hospital del Mar, Barcelona, Not set

Hospital Universitario Vall d'Hebron, Barcelona, Not set

Institut Catala d'Oncologia - L'Hospitalet, Barcelona, Not set

Hospital General Universitario Gregorio Maranon, Madrid, Not set

Hospital Universitario Ramon y Cajal, Madrid, Not set

Hospital Universitario 12 de Octubre, Madrid, Not set

Hospital Regional Universitario de Malaga, Malaga, Not set

National Taiwan University Hospital Hsin-Chu Branch, Hsinchu, Not set

National Taiwan University Hospital, Taipei, Not set

Conditions: Pancreatic Ductal Adenocarcinoma, Non-small Cell Lung Cancer, Colorectal Cancer, Advanced Solid Tumor, Metastatic Solid Tumor

Learn More ›

Browse by State

Non-Small Cell Lung Cancer clinical trials in Alabama

Non-Small Cell Lung Cancer clinical trials in Alaska

Non-Small Cell Lung Cancer clinical trials in Arizona

Non-Small Cell Lung Cancer clinical trials in Arkansas

Non-Small Cell Lung Cancer clinical trials in California

Non-Small Cell Lung Cancer clinical trials in Colorado

Non-Small Cell Lung Cancer clinical trials in Connecticut

Non-Small Cell Lung Cancer clinical trials in Delaware

Non-Small Cell Lung Cancer clinical trials in District of Columbia

Non-Small Cell Lung Cancer clinical trials in Florida

Non-Small Cell Lung Cancer clinical trials in Georgia

Non-Small Cell Lung Cancer clinical trials in Hawaii

Non-Small Cell Lung Cancer clinical trials in Idaho

Non-Small Cell Lung Cancer clinical trials in Illinois

Non-Small Cell Lung Cancer clinical trials in Indiana

Non-Small Cell Lung Cancer clinical trials in Iowa

Non-Small Cell Lung Cancer clinical trials in Kansas

Non-Small Cell Lung Cancer clinical trials in Kentucky

Non-Small Cell Lung Cancer clinical trials in Louisiana

Non-Small Cell Lung Cancer clinical trials in Maine

Non-Small Cell Lung Cancer clinical trials in Montana

Non-Small Cell Lung Cancer clinical trials in Nebraska

Non-Small Cell Lung Cancer clinical trials in Nevada

Non-Small Cell Lung Cancer clinical trials in New Hampshire

Non-Small Cell Lung Cancer clinical trials in New Jersey

Non-Small Cell Lung Cancer clinical trials in New Mexico

Non-Small Cell Lung Cancer clinical trials in New York

Non-Small Cell Lung Cancer clinical trials in North Carolina

Non-Small Cell Lung Cancer clinical trials in North Dakota

Non-Small Cell Lung Cancer clinical trials in Ohio

Non-Small Cell Lung Cancer clinical trials in Oklahoma

Non-Small Cell Lung Cancer clinical trials in Oregon

Non-Small Cell Lung Cancer clinical trials in Maryland

Non-Small Cell Lung Cancer clinical trials in Massachusetts

Non-Small Cell Lung Cancer clinical trials in Michigan

Non-Small Cell Lung Cancer clinical trials in Minnesota

Non-Small Cell Lung Cancer clinical trials in Mississippi

Non-Small Cell Lung Cancer clinical trials in Missouri

Non-Small Cell Lung Cancer clinical trials in Pennsylvania

Non-Small Cell Lung Cancer clinical trials in Rhode Island

Non-Small Cell Lung Cancer clinical trials in South Carolina

Non-Small Cell Lung Cancer clinical trials in South Dakota

Non-Small Cell Lung Cancer clinical trials in Tennessee

Non-Small Cell Lung Cancer clinical trials in Texas

Non-Small Cell Lung Cancer clinical trials in Utah

Non-Small Cell Lung Cancer clinical trials in Vermont

Non-Small Cell Lung Cancer clinical trials in Virginia

Non-Small Cell Lung Cancer clinical trials in Washington

Non-Small Cell Lung Cancer clinical trials in West Virginia

Non-Small Cell Lung Cancer clinical trials in Wisconsin

Non-Small Cell Lung Cancer clinical trials in Wyoming